Yili stock costs CNY 27.96, 20.2 percent below fair value

Published on 10/12/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yili stock traded at CNY 27.96 on October 12, 2026 versus CNY 33.60 fair value. Morningstar set CNY 33.60 fair value on October 2, 2026.

Key points in brief

Yili stock was last at CNY 27.96 on October 12, 2026, while Morningstar's fair value estimate was CNY 33.60.
Morningstar rated Yili its preferred pick among China's two largest dairy processors in an October 2, 2026 analyst note.
First-half 2026 revenue reached CNY 64.49 billion, up 4.13 percent year over year, while net profit fell 20.02 percent.
Yili's market capitalization was CNY 176.9 billion and its price-to-earnings ratio was 17.5 on October 12, 2026.
The next earnings date listed for Yili is October 30, 2026.

Yili, CNE000000JP5, Illustration mit AI erstellt.

Yili stock (ISIN CNE000000JP5) was last at CNY 27.96 on the Shanghai Stock Exchange on October 12, 2026, 20.2 percent below Morningstar's CNY 33.60 fair value estimate dated October 2, 2026. The analyst note named Yili its preferred pick among China's two largest dairy processors, giving the valuation gap a clear market reference.

Price sits below fair value

The CNY 27.96 quote places the stock 6.1 percent below its CNY 29.78 52-week high and 17.7 percent above its CNY 23.76 52-week low. Its market capitalization was CNY 176.9 billion, while the price-to-earnings ratio stood at 17.5 on October 12, 2026.

Morningstar also described the coverage transfer as a narrow-moat assessment and identified Yili as its preferred pick on October 2, 2026. The CNY 33.60 estimate implies a 20.2 percent gap above the October 12 quote.

Revenue grows as profit falls

Stockinsky reported that Yili's first-half 2026 revenue reached CNY 64.49 billion, up 4.13 percent from the year-earlier period. Net profit attributable to shareholders fell 20.02 percent to CNY 5.76 billion, with the report citing CNY 2.46 billion of asset impairment provisions, including CNY 1.55 billion linked to Ausnutria.

The split between sales and profit is the key market issue. Revenue growth remained positive, but the impairment charge weakened reported earnings and makes the valuation comparison more dependent on the quality and persistence of underlying operating profit.

Comparison with peers

Yili (SSE, CNY): P/E 17.5, market capitalization CNY 176.9 billion

Kweichow Moutai (SSE, CNY): plus 2.0 percent, P/E 19.8, market capitalization CNY 1.6 trillion

New Hope Dairy (SZSE, CNY): minus 1.0 percent, P/E 16.3, market capitalization CNY 13.0 billion

Next date and market context

Investing.com lists October 30, 2026 as Yili's next earnings date. That report will give investors a fresh test of whether revenue growth can offset the profit pressure recorded in the first half of 2026.